HIV Prevention Jab: Health Minister Praises, Warns of Supply Issues
Here’s a breakdown of the key information from the provided text, focusing on South Africa‘s access to lenacapavir and related issues:
1. Lenacapavir Access & Funding:
* New HIV Prevention: South Africa is rolling out lenacapavir, a new HIV prevention medication, with support from Gilead Sciences. though,initial supply is expected to be limited.
* Prioritization: The goverment plans to prioritize vulnerable populations in high-burden districts to maximize impact.
* Price Reduction: Gilead lowered the price of lenacapavir from an initial estimate of $28,000-$40,000 per person annually, but South Africa aims for independent funding.
* Long-Term sustainability: Integration into the national essential medicines list is crucial for long-term funding.
2. Concerns about US Funding Cuts:
* Impact on Health System: south africa’s health system was considerably weakened by abrupt funding cuts from USAID and othre US government sources in early 2025.
* HIV/AIDS & TB Programs Affected: These cuts severely impacted HIV/AIDS and tuberculosis treatment, prevention, and research programs.
* Caution Against Complacency: The minister cautioned against complacency, given the funding situation.
3. Gilead’s Licensing & South African Exclusion:
* Generic Production: Gilead has granted voluntary, royalty-free licenses to pharmaceutical companies in Egypt, pakistan, and India to produce generic lenacapavir.
* South Africa Excluded: South African companies were not included in these licensing agreements, despite participating in clinical trials.
* Civil Society Outrage: This exclusion has sparked anger from civil society groups.
* “Ubuntu” Principle: Sheila Mbele-Khama (SANAC) criticized the exclusion,stating it violates the South African philosophy of “ubuntu” (human dignity and fairness).
* disproportionate Impact: SANAC claims that 25% of new HIV infections occur in the 26 countries Gilead didn’t grant licenses to.
4. Other Prevention Methods:
* WHO Recommendation: The World Health Institution recommended a six-month HIV prevention jab (already approved in the US and Europe) as an additional prevention option.
* Gilead’s Registration efforts: Gilead is expediting registration of lenacapavir in 18 high-incidence countries, including South Africa, until generic versions become available in 2027.
in essence, the article highlights South Africa’s progress in gaining access to a new HIV prevention tool, but also underscores the challenges of funding, the impact of external aid cuts, and the ethical concerns surrounding Gilead’s licensing practices.